Loading company…
Beijing-based Pheromonicin Biotech develops antibiotics that target drug-resistant bacteria through its flagship product, Pheromonicin.
Founded in 2008 and headquartered in Beijing, China, Pheromonicin Biotech develops antibiotic solutions. Its flagship Pheromonicin targets drug-resistant bacteria by creating lethal ion channels in bacterial cell membranes, and it is being developed for resistant infections, anti-fungal and cancer research, and agricultural uses. The company licenses its technology to pharmaceutical firms and is led by CEO Rongqi Li. SAIF Partners invested in a Series A round on June 1, 2010.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in